{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T20:10:38Z","timestamp":1770495038145,"version":"3.49.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.beem.2022.101662","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T02:42:08Z","timestamp":1650595328000},"page":"101662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Morbidity and mortality in men: Role of androgens"],"prefix":"10.1016","volume":"36","author":[{"given":"Giuseppe","family":"Fallara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Belladelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Boeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Capogrosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2022.101662_bib1","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(13)61126-5","article-title":"Male hypogonadism","volume":"383","author":"Basaria","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2022.101662_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0911101","article-title":"Identification of late-onset hypogonadism in middle-aged and elderly men","volume":"363","author":"Wu","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101662_bib3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1210\/jc.2006-1859","article-title":"The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men","volume":"92","author":"Travison","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ucl.2016.01.002","article-title":"Hypogonadism its prevalence and diagnosis","volume":"43","author":"Ross","year":"2016","journal-title":"Urol Clin N Am"},{"key":"10.1016\/j.beem.2022.101662_bib5","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1210\/jc.2003-031719","article-title":"Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study","volume":"89","author":"Araujo","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib6","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1210\/jc.2009-1796","article-title":"Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study","volume":"95","author":"Tajar","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/andr.12947","article-title":"Male factor infertility trends throughout the last 10 years: report from a tertiary-referral academic andrology centre","volume":"9","author":"Fallara","year":"2021","journal-title":"Andrology-Us"},{"key":"10.1016\/j.beem.2022.101662_bib8","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an endocrine society\u2217 clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11154-021-09630-8","article-title":"Diabetes is most important cause for mortality in COVID-19 hospitalized patients: systematic review and meta-analysis","volume":"22","author":"Corona","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.beem.2022.101662_bib10","doi-asserted-by":"crossref","first-page":"17473","DOI":"10.1038\/s41598-021-96875-7","article-title":"A\u00a0virus-free cellular model recapitulates several features of severe COVID-19","volume":"11","author":"Lavorgna","year":"2021","journal-title":"Sci Rep-Uk"},{"key":"10.1016\/j.beem.2022.101662_bib11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1210\/jcem.87.2.8201","article-title":"Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study","volume":"87","author":"Feldman","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1210\/jc.2010-0266","article-title":"Why is androgen replacement in males controversial?","volume":"96","author":"Cunningham","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib13","first-page":"812","article-title":"Testosterone deficiency: a review and comparison of current guidelines","volume":"16","author":"Kwong","year":"2019","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.beem.2022.101662_bib14","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1093\/eurheartj\/ehq009","article-title":"Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20\u201379","volume":"31","author":"Haring","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2022.101662_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2021.06.007","article-title":"European association of urology guidelines on sexual and reproductive health\u20142021 update: male sexual dysfunction","author":"Salonia","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.beem.2022.101662_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40264-015-0348-y","article-title":"Testosterone replacement therapy and mortality in older men","volume":"39","author":"Hackett","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.beem.2022.101662_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5534\/wjmh.2013.31.2.103","article-title":"Risks and benefits of late onset hypogonadism treatment: an expert opinion","volume":"31","author":"Corona","year":"2013","journal-title":"World J Men\u2019s Health"},{"key":"10.1016\/j.beem.2022.101662_bib18","first-page":"1260","article-title":"Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies","volume":"15","author":"Corona","year":"2018","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.beem.2022.101662_bib19","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/humupd\/dmx012","article-title":"Prevalence of \u2018obesity-associated gonadal dysfunction\u2019 in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis","volume":"23","author":"Escobar-Morreale","year":"2017","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.beem.2022.101662_bib20","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/hrt.2010.210757","article-title":"Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis","volume":"97","author":"Ruige","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.beem.2022.101662_bib21","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1210\/jc.2011-1137","article-title":"Endogenous testosterone and mortality in men: a systematic review and meta-analysis","volume":"96","author":"Araujo","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5534\/wjmh.2015.33.3.130","article-title":"Testosterone replacement therapy and cardiovascular risk: a review","volume":"33","author":"Corona","year":"2015","journal-title":"World J Men\u2019s Health"},{"key":"10.1016\/j.beem.2022.101662_bib23","first-page":"820","article-title":"Testosterone and cardiovascular risk: meta-analysis of interventional studies","volume":"15","author":"Corona","year":"2018","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.beem.2022.101662_bib24","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1517\/14740338.2014.950653","article-title":"Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis","volume":"13","author":"Corona","year":"2014","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.beem.2022.101662_bib25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/M19-0830","article-title":"Efficacy and safety of testosterone treatment in men: an evidence report for a clinical practice guideline by the American College of physicians","volume":"172","author":"Diem","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2022.101662_bib26","doi-asserted-by":"crossref","first-page":"e625","DOI":"10.1210\/clinem\/dgaa743","article-title":"Serum testosterone is inversely and sex hormone-binding globulin is directly associated with all-cause mortality in men","volume":"106","author":"Yeap","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","article-title":"Adverse events associated with testosterone administration","volume":"363","author":"Basaria","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101662_bib28","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2013.280386","article-title":"Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels","volume":"310","author":"Vigen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2022.101662_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085805","article-title":"Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men","volume":"9","author":"Finkle","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2022.101662_bib30","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJMc1009326","article-title":"Adverse events associated with testosterone administration","volume":"363","author":"Khoo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101662_bib31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/phar.1534","article-title":"Testosterone therapy and risk of myocardial infarction: a pharmacoepidemiologic study","volume":"35","author":"Etminan","year":"2015","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.beem.2022.101662_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-11-108","article-title":"Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials","volume":"11","author":"Xu","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.beem.2022.101662_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-014-0211-5","article-title":"Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis","volume":"12","author":"Borst","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.beem.2022.101662_bib34","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.2016.21043","article-title":"Testosterone treatment and coronary artery plaque volume in older men with low testosterone","volume":"317","author":"Budoff","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2022.101662_bib35","series-title":"FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use","year":"2015"},{"key":"10.1016\/j.beem.2022.101662_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/cen.14442","article-title":"Effects of testosterone treatment, with and without exercise training, on ambulatory blood pressure in middle-aged and older men","volume":"95","author":"Chasland","year":"2021","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101662_bib37","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/gerona\/60.11.1451","article-title":"Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials","volume":"60","author":"Calof","year":"2005","journal-title":"J\u00a0Gerontol Ser"},{"key":"10.1016\/j.beem.2022.101662_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2017.04.017","article-title":"Interventions in type 2 diabetes mellitus and cardiovascular mortality\u2013An overview of clinical trials","volume":"42","author":"Burggraaf","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.beem.2022.101662_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ahj.2021.11.016","article-title":"Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study","volume":"245","author":"Bhasin","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.beem.2022.101662_bib40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.mce.2013.09.017","article-title":"Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits","volume":"382","author":"Morelli","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.beem.2022.101662_bib41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.mce.2014.01.014","article-title":"Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit","volume":"384","author":"Vignozzi","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.beem.2022.101662_bib42","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/pros.22623","article-title":"Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation","volume":"73","author":"Vignozzi","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.beem.2022.101662_bib43","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40618-014-0051-3","article-title":"Benign prostatic hyperplasia: a new metabolic disease?","volume":"37","author":"Vignozzi","year":"2014","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101662_bib44","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2022.101662_bib45","doi-asserted-by":"crossref","first-page":"183041","DOI":"10.1155\/2013\/183041","article-title":"Testosterone-induced effects on lipids and inflammation","volume":"2013","author":"Vodo","year":"2013","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.beem.2022.101662_bib46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12902-016-0109-7","article-title":"Predictive value of serum testosterone for type 2 diabetes risk assessment in men","volume":"16","author":"Atlantis","year":"2016","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.beem.2022.101662_bib47","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00592-018-1163-6","article-title":"The role of sex hormone-binding globulin (SHBG), testosterone, and other sex steroids, on the development of type 2 diabetes in a cohort of community-dwelling middle-aged to elderly men","volume":"55","author":"Gyawali","year":"2018","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.beem.2022.101662_bib48","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1210\/jc.2004-1158","article-title":"Endogenous sex hormones and metabolic syndrome in aging men","volume":"90","author":"Muller","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib49","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/obr.12282","article-title":"Testosterone and obesity","volume":"16","author":"Kelly","year":"2015","journal-title":"Obes Rev"},{"key":"10.1016\/j.beem.2022.101662_bib50","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2605.2010.01117.x","article-title":"Type 2 diabetes mellitus and testosterone: a meta-analysis study","volume":"34","author":"Corona","year":"2011","journal-title":"Int J Androl"},{"key":"10.1016\/j.beem.2022.101662_bib51","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1210\/jc.2004-0804","article-title":"Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes","volume":"89","author":"Dhindsa","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib52","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.2337\/dc09-1649","article-title":"Testosterone concentrations in diabetic and nondiabetic obese men","volume":"33","author":"Dhindsa","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2022.101662_bib53","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2337\/dc06-1426","article-title":"Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes","volume":"30","author":"Kapoor","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2022.101662_bib54","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1210\/jc.2007-2177","article-title":"Low testosterone levels are common and associated with insulin resistance in men with diabetes","volume":"93","author":"Grossmann","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib55","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jama.295.11.1288","article-title":"Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis","volume":"295","author":"Ding","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2022.101662_bib56","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2337\/diacare.27.5.1036","article-title":"Testosterone and sex hormone\u2013binding globulin predict the metabolic syndrome and diabetes in middle-aged men","volume":"27","author":"Laaksonen","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2022.101662_bib57","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2337\/dc08-0851","article-title":"Testosterone concentration in young patients with diabetes","volume":"31","author":"Chandel","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2022.101662_bib58","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3810\/pgm.2009.05.2001","article-title":"Hypogonadotropic hypogonadism in men with type 2 diabetes","volume":"121","author":"Dandona","year":"2015","journal-title":"Postgrad Med"},{"key":"10.1016\/j.beem.2022.101662_bib59","first-page":"997","article-title":"Pathogenesis of the decreased androgen levels in obese men","volume":"79","author":"Giagulli","year":"1994","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib60","first-page":"3673","article-title":"Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels\u2217","volume":"84","author":"Isidori","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib61","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1742-1241.2006.00992.x","article-title":"Prevalence of hypogonadism in males aged at least 45 years: the HIM study","volume":"60","author":"Mulligan","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.beem.2022.101662_bib62","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1210\/en.2003-0644","article-title":"Hypothalamic interleukin-1\u03b2 and tumor necrosis factor-\u03b1, but not interleukin-6, mediate the endotoxin-induced suppression of the reproductive Axis in rats","volume":"144","author":"Watanobe","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2022.101662_bib63","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1046\/j.1365-2826.2001.00632.x","article-title":"The in\u00a0vitro role of tumour necrosis factor-alpha and interleukin-6 in the hypothalamic-pituitary gonadal Axis","volume":"13","author":"Russell","year":"2001","journal-title":"J\u00a0Neuroendocrinol"},{"key":"10.1016\/j.beem.2022.101662_bib64","first-page":"126","article-title":"Evidence for a common genetic origin of classic and milder adult-onset forms of isolated hypogonadotropic hypogonadism","volume":"8","author":"Cangiano","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.beem.2022.101662_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/tam.6.1.1.7","article-title":"Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency","volume":"6","author":"Boyanov","year":"2003","journal-title":"Aging Male Off J Int Soc Study Aging Male"},{"key":"10.1016\/j.beem.2022.101662_bib66","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2337\/dc10-1233","article-title":"Testosterone replacement in hypogonadal men with type 2 diabetes and\/or metabolic syndrome (the TIMES2 study)","volume":"34","author":"Jones","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2022.101662_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13685538.2018.1468429","article-title":"The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes","volume":"21","author":"Groti","year":"2018","journal-title":"Aging Male"},{"key":"10.1016\/j.beem.2022.101662_bib68","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/eje.1.02166","article-title":"Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes","volume":"154","author":"Kapoor","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101662_bib69","first-page":"840","article-title":"Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study","volume":"11","author":"Hackett","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.beem.2022.101662_bib70","first-page":"726","article-title":"Fifty- two\u2014week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone","volume":"30","author":"Heufelder","year":"2009","journal-title":"J\u00a0Androl"},{"key":"10.1016\/j.beem.2022.101662_bib71","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40001-014-0056-6","article-title":"Influence of testosterone replacement therapy on metabolic disorders in male patients with type 2 diabetes mellitus and androgen deficiency","volume":"19","author":"Janjgava","year":"2014","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.beem.2022.101662_bib72","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2337\/dc18-2388","article-title":"Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: eight-year data from a registry study","volume":"42","author":"Yassin","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2022.101662_bib73","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S2213-8587(20)30367-3","article-title":"Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial","volume":"9","author":"Wittert","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2022.101662_bib74","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.2337\/dc13-2845","article-title":"Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial","volume":"37","author":"Gianatti","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2022.101662_bib75","doi-asserted-by":"crossref","first-page":"570","DOI":"10.4158\/EP09355.OR","article-title":"Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus","volume":"16","author":"Gopal","year":"2010","journal-title":"Endocr Pract"},{"key":"10.1016\/j.beem.2022.101662_bib76","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/dom.12701","article-title":"Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy","volume":"18","author":"Magnussen","year":"2016","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib77","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/cen.13084","article-title":"Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review","volume":"85","author":"Albert","year":"2016","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2022.101662_bib78","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/1756287215597633","article-title":"Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk","volume":"7","author":"Michaud","year":"2015","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.beem.2022.101662_bib79","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.eururo.2018.07.024","article-title":"Low free testosterone and prostate cancer risk: a collaborative analysis of 20 prospective studies","volume":"74","author":"Watts","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.beem.2022.101662_bib80","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bju.13417","article-title":"Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis","volume":"118","author":"Boyle","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.beem.2022.101662_bib81","first-page":"1787","article-title":"Diagnosis and treatment of testosterone deficiency: recommendations from the fourth international consultation for sexual medicine (ICSM 2015)","volume":"13","author":"Khera","year":"2016","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.beem.2022.101662_bib82","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-019-0087-y","article-title":"Paediatric and adult-onset male hypogonadism","volume":"5","author":"Salonia","year":"2019","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.beem.2022.101662_bib83","first-page":"80","article-title":"Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries","volume":"193","author":"Haider","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.beem.2022.101662_bib84","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S2213-8587(16)00112-1","article-title":"Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study","volume":"4","author":"Wallis","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2022.101662_bib85","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bju.12756","article-title":"Testosterone therapy and cancer risk","volume":"115","author":"Eisenberg","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.beem.2022.101662_bib86","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12672-018-0351-8","article-title":"Aggressiveness of localized prostate cancer: the key value of testosterone deficiency evaluated by both total and bioavailable testosterone: AndroCan study results","volume":"10","author":"Neuzillet","year":"2019","journal-title":"Hormones Cancer"},{"key":"10.1016\/j.beem.2022.101662_bib87","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of Dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101662_bib88","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-11-2799","article-title":"Serum sex steroids depict a nonlinear U-shaped association with high-risk prostate cancer at radical prostatectomy","volume":"18","author":"Salonia","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beem.2022.101662_bib89","first-page":"637","article-title":"Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: a systematic literature review and meta-analysis","volume":"37","author":"Parizi","year":"2019","journal-title":"Urol Oncol Semin Orig Invest"},{"key":"10.1016\/j.beem.2022.101662_bib90","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1210\/jc.2013-2052","article-title":"Late-onset hypogonadism and mortality in aging men","volume":"99","author":"Pye","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib91","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1210\/jc.2015-2460","article-title":"The association of reproductive hormone levels and all-cause, cancer, and cardiovascular disease mortality in men","volume":"100","author":"Holmboe","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib92","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/andr.12993","article-title":"Severely low testosterone in males with COVID-19: a case-control study","volume":"9","author":"Salonia","year":"2021","journal-title":"Andrology-Us"},{"key":"10.1016\/j.beem.2022.101662_bib93","first-page":"1775","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy","volume":"323","author":"Onder","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2022.101662_bib94","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00392-020-01626-9","article-title":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China","volume":"109","author":"Li","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.beem.2022.101662_bib95","doi-asserted-by":"crossref","first-page":"154252","DOI":"10.1016\/j.metabol.2020.154252","article-title":"Commentary: testosterone, a key hormone in the context of COVID-19 pandemic","volume":"108","author":"Pozzilli","year":"2020","journal-title":"Metabolis"},{"key":"10.1016\/j.beem.2022.101662_bib96","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jaad.2020.04.032","article-title":"SARS-COV-2 infection is likely to be androgen mediated","volume":"83","author":"Wambier","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.beem.2022.101662_bib97","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/JVI.02202-13","article-title":"TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein","volume":"88","author":"Heurich","year":"2013","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.beem.2022.101662_bib98","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.beem.2022.101662_bib99","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.beem.2022.101662_bib100","first-page":"1","article-title":"The relationship between circulating testosterone and inflammatory cytokines in men","volume":"22","author":"Mohamad","year":"2018","journal-title":"Aging Male"},{"key":"10.1016\/j.beem.2022.101662_bib101","first-page":"116","article-title":"The relationship between testosterone and molecular markers of inflammation in older men","volume":"28","author":"Maggio","year":"2005","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2022.101662_bib102","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1210\/jc.2018-02697","article-title":"Functional hypogonadotropic hypogonadism in men: underlying neuroendocrine mechanisms and natural history","volume":"104","author":"Dwyer","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101662_bib103","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/andr.12821","article-title":"Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients","volume":"9","author":"Rastrelli","year":"2021","journal-title":"Andrology-Us"},{"key":"10.1016\/j.beem.2022.101662_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13685538.2020.1807930","article-title":"Effect of serum total testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease 2019 (COVID-19) in SARS-CoV-2 infected male patients: a cohort study","volume":"23","author":"\u00c7ayan","year":"2020","journal-title":"Aging Male"},{"key":"10.1016\/j.beem.2022.101662_bib105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/andr.12811","article-title":"SARS-CoV-2, testosterone and frailty in males (PROTEGGIMI): a multidimensional research project","volume":"9","author":"Salonia","year":"2021","journal-title":"Andrology-Us"},{"key":"10.1016\/j.beem.2022.101662_bib106","series-title":"Andrological effects of SARS-Cov2 infection: a systematic review and meta-analysis","author":"Corona","year":"2022"},{"key":"10.1016\/j.beem.2022.101662_bib107","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.annonc.2020.04.479","article-title":"Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)","volume":"31","author":"Montopoli","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beem.2022.101662_bib108","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.annonc.2020.06.015","article-title":"Androgen deprivation and SARS-CoV-2 in men with prostate cancer","volume":"31","author":"Koskinen","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beem.2022.101662_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255966","article-title":"Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic","volume":"16","author":"Gedeborg","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2022.101662_bib110","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.annonc.2020.06.005","article-title":"On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2","volume":"31","author":"Caffo","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beem.2022.101662_bib111","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/andr.13097","article-title":"Testosterone in males with COVID-19: a 7-month cohort study","volume":"10","author":"Salonia","year":"2022","journal-title":"Andrology-Us"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:58:55Z","timestamp":1761497935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22000495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":111,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1521690X22000495"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101662","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Morbidity and mortality in men: Role of androgens","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101662"}}